LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

BioNTech SE ADR

Geschlossen

BrancheGesundheitswesen

108.63 -1.29

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

108.25

Max

110.29

Schlüsselkennzahlen

By Trading Economics

Einkommen

-747M

-445M

Verkäufe

-1B

183M

EPS

-1.821

Gewinnspanne

-243.654

Angestellte

6,772

EBITDA

-833M

-369M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+25.97% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2B

27B

Vorheriger Eröffnungskurs

109.92

Vorheriger Schlusskurs

108.63

Nachrichtenstimmung

By Acuity

92%

8%

367 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

BioNTech SE ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juni 2025, 11:48 UTC

Wichtige Markttreiber

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

4. Feb. 2025, 18:52 UTC

Wichtige Markttreiber

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15. Nov. 2024, 10:28 UTC

Wichtige Markttreiber

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

20. Mai 2025, 14:46 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

5. Mai 2025, 15:13 UTC

Market Talk
Ergebnisse

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

15. Nov. 2024, 11:14 UTC

Market Talk

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15. Nov. 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5. Aug. 2024, 10:02 UTC

Ergebnisse

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5. Aug. 2024, 10:01 UTC

Ergebnisse

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5. Aug. 2024, 10:01 UTC

Ergebnisse

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5. Aug. 2024, 10:00 UTC

Ergebnisse

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5. Aug. 2024, 09:59 UTC

Ergebnisse

BioNTech 2Q Loss EUR807.8M >BNTX

5. Aug. 2024, 09:59 UTC

Ergebnisse

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5. Aug. 2024, 09:59 UTC

Ergebnisse

BioNTech 2Q Rev EUR128.7M >BNTX

Peer-Vergleich

Kursveränderung

BioNTech SE ADR Prognose

Kursziel

By TipRanks

25.97% Vorteil

12-Monats-Prognose

Durchschnitt 140 USD  25.97%

Hoch 181 USD

Tief 110 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioNTech SE ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

19 ratings

14

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

92.4 / 103.5Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

367 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac